Therefore, new-generation nanoscale SYK inhibitors capable of better TME infiltration [85] (Figure 4) show clinical impact potential not only because of their cytotoxic activity but also because of their potential to abrogate the WNT5A-mediated MM adhesion to the protective stroma of the TME. This evidence concerns the gene SYK and Miyoshi myopathy.